X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development Clinical Trials

Boehringer Ingelheim Announces Completed Enrollment of Phase III Clinical Trial for Biosimilar Candidate to Adalimumab

Yuvraj_pawp by Yuvraj_pawp
19th November 2015
in Clinical Trials

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Phase III clinical trial for BI695501, a biosimilar candidate for AbbVie’s Humira®, fully enrolled

Recently announced Phase I trial results show pharmacokinetic bioequivalence of BI695501 to U.S.-licensed and EU-approved adalimumab reference products1A

First scientific data presentation for a Boehringer Ingelheim biosimilar compound at the ACR/ARHP Annual Meeting

Ingelheim, Germany, November 10, 2015 — Boehringer Ingelheim today announced it has completed enrollment for the pivotal Phase III trial (NCT02137226) of BI695501, a biosimilar candidate to adalimumab (AbbVie’s Humira®). This announcement was made following recent results from a Phase I trial that demonstrated pharmacokinetic bioequivalence with both the U.S.-licensed and EU- approved reference products.1A These Phase I data for BI695501 were discussed today at the American College of Rheumatology / Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in San Francisco.

The Phase III clinical trial is a randomized, double-blind, parallel arm, multiple dose, active comparator trial in patients2A who have been diagnosed with moderate to severe rheumatoid arthritis and are currently being treated with methotrexate.2B Each participant is randomized to receive either BI695501 or the U.S.-licensed reference product every two weeks for 48 weeks.

“We are excited to reach this important milestone for BI695501, which brings us closer to our goal of delivering new options to patients through our investigational biosimilars portfolio,” said Sandeep Athalye, MD, Vice President and Head, Clinical Development and Medical Affairs Biosimilars, Boehringer Ingelheim. “Our long-term commitment is to become a global leader in biosimilars, thereby supporting access to biologic medicines around the world.”

Results for the completed Phase I study for adalimumab were announced on October 28.

About Boehringer Ingelheim in Biologics

Boehringer Ingelheim is one of the largest producers of biologic medicines in the world. As a pioneer in biologics with more than 35 years of experience, the company has brought more than 20 biologic medicines to patients around the world.3 Boehringer Ingelheim is committed to becoming a global leader in biosimilars and increasing the availability of high quality biologics.

About Rheumatoid Arthritis

Rheumatoid Arthritis (RA) is a chronic inflammatory autoimmune disease affecting synovial joint lining; causing pain, stiffness, swelling and limited motion and function of joints.4 In many patients, the progressive destruction of joints may ultimately result in disability. Three times as many women are affected by RA compared to men. RA affects approximately 23.7 million people worldwide5 and 1.6 million people in the United States.6,7 It can develop at any time during adulthood, but it usually occurs between 40 and 70 years of age.

Previous Post

Real-World Analysis of more than 44,000 Patients Reinforces Safety and Effectiveness of Pradaxa® in Routine Clinical Care

Next Post

Boehringer Ingelheim partners with leading scientific institutions in inflammatory bowel disease research

Related Posts

Tissue Repair Drug
Clinical Trials

FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

7th October 2025
Breast Cancer Therapy
Clinical Trials

US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

27th September 2025
Sensor Technology
Clinical Trials

Enhancing Clinical Research with Advanced Sensor Technology

11th September 2025
Agentic AI in Pharma Transforming RD to Commercialisation
Clinical Trials

Agentic AI in Pharma: Transforming R&D to Commercialisation

31st July 2025
The Future of Clinical
Clinical Trials

The Future of Clinical Trial Data in Decentralisation Models

30th July 2025
Aptar Pharma Bolsters Clinical Trial.
Clinical Trials

Aptar Pharma Bolsters Clinical Trial Capabilities with Strategic Materials Manufacturing Acquisition

24th July 2025
Next Post

Boehringer Ingelheim partners with leading scientific institutions in inflammatory bowel disease research

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In